Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

PWRM, ALNY, EPAX, ADPI- Stock Reports! from

Stock-PR Reporting



FREE Daily Stock Alerts From



Power3 Medical Products, Inc. (OTC:PWRM)

PWRM recently delivered four poster presentations at the 2010 ICAD. These presentations discussed PWRM’s diagnostic test, NuroPro, and focused on PWRM’s Alzheimer’s disease blood serum biomarkers, test and clinical validation trials.

“In preparation for commercialization, our objective at this meeting was to show how Power3 ’s protein biomarkers and blood tests provide superior solutions for diagnosis and drug response to improve the treatment of Alzheimer’s disease,” stated Dr. Ira L. Goldknopf, PWRM ’s President & Chief Scientific Officer. “It was gratifying to receive substantial attention to our posters from representatives of major pharma and clinical research institutions from around the world. They expressed surprise and enthusiasm for our findings, especially those relating to the methods by which Power3’s protein biomarkers indicate how patients respond to treatment with the three major anti-dementia drugs.”

“We are pleased that our blood tests specifically diagnose Alzheimer’s in patients, both pre- and post-treatment,” commented Helen R. Park, MS, CEO of PWRM, “and that our scientific collaborators, Dr. Marwan Sabbagh, Medical and Scientific Director of the Banner Sun Health Medical Research Institute, and Dr. Lourdes R. Bosquez, President of the Woodlands Behavioral Institute, Inc., presented along with us at the meeting in Hawaii.”

“We are within striking distance of realizing an Alzheimer’s clinical diagnostic tool which I hope will lead to a greater understanding of the disease and buoy the pace of future therapeutic interventions,” added Marwan Sabbagh MD, Medical and Scientific Director of Banner Sun Health Medical Research Institute.

PWRM has filed several patent applications that are currently pending for its NuroPro technology. PWRM also has a world-wide exclusive license from the Baylor College of Medicine in Houston, Texas. To date, PWRM has given 9 presentations on NuroPro at international scientific meetings in the United States, Europe and China. PWRM has also published 6 articles on NuroPro in peer-reviewed scientific journals. PWRM intends to publish these latest findings as well.


Power3 Medical Products, Inc. strives to become the premier biotechnology company specializing in the commercialization of proteomics IP for the diagnosis and treatment of disease by using cutting edge technologies, world class quality procedures and superior research methodologies. PWRM will be guided in all of its dealings with its customers, partners, shareholders, associates and investors by the philosophy of best practices.


Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY) presented new data at the 2010 International Chemical Congress of Pacific Basin Societies (Pacifichem), being held in Honolulu, Hawaii, December 15-20. New data show recent progress in the company’s delivery efforts with siRNAs as well as results related to the translation of RNAi therapeutics in human clinical studies, specifically with the company’s ALN-VSP liver cancer program.
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics based on RNA interference (RNAi). Its lead RNAi therapeutic program includes ALN-RSV01, which is in Phase II clinical trial for the treatment of human respiratory syncytial virus (RSV) infection.

Ambassadors Group Inc. (Nasdaq:EPAX) announced that on December 13, 2010, it repurchased 666,724 shares of its common stock for approximately $7.3 million, or $11.00 per share. The transaction took place through a negotiated block purchase. The Company executed the transaction under previously announced buyback authorizations by its Board of Directors.
Ambassadors Group, Inc., an educational company, organizes and promotes educational travel and sports programs for students, athletes, and professionals. The company, through its subsidiaries, offers Student Ambassador Programs, which provide opportunities for grade school, middle school, and high school students to travel to domestic and foreign destinations to learn about the history, government, economy, and culture of such countries; and Sports Ambassador Programs that offer opportunities for student athletes in middle school and high school to participate in international tournaments.

American Dental Partners, Inc. (Nasdaq:ADPI) announced on Dec 16, 2010 that Texas Tooth Doctor for Kids has been accredited by the Accreditation Association for Ambulatory Health Care ("AAAHC"). Texas Tooth Doctor for Kids is a dental group practice providing dental care to children in San Antonio and Houston. "Texas Tooth Doctor for Kids' accreditation is well-deserved and is recognition of their commitment to high quality standards and clinical excellence," said Gregory A. Serrao, Chief Executive Officer.
American Dental Partners, Inc. provides dental facilities, support staff, and business services to multidisciplinary dental group practices in the United States. The company acquires assets of the dental practices, with which it affiliates and enters into long-term service agreements with professional corporations, professional associations, or service corporations.



Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at Equity Holdings Inc. (OTCPK:CRWE) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (OTCPK:CRWE), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (OTCPK:CRWE) advertises for a particular client, Crown Equity Holdings Inc. (OTCPK:CRWE) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (OTCPK:CRWE), if paid in stock, can and may sell those securities during the advertising period. Crown Equity Holdings Inc. (OTCPK:CRWE) has received 1,000,000 shares 144 restricted stocks for IT department services and 2,000,000 shares (free trade) for 12 months of video production from Power 3 Medical Products Inc. (OTC:PWRM).

Sign Up For Free Stock Alerts At


Be Sure To Visit


The views expressed in any article, reports, writings are not necessarily the views of Crown Equity Holdings Inc. its officers, directors, staff, contractors or employees. They do not represent the views or opinions of this site. Views expressed in articles are those of the author alone.